Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05573035 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate LYL845 in Adults With Solid Tumors
A Phase 1 study, sponsored by Lyell Immunopharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT05573035 is a Phase 1 study that was terminated before completion, run by Lyell Immunopharma. The registered enrollment target is 39 participants.
The verdict
NCT05573035, a Phase 1 study, was terminated before completion, sponsored by Lyell Immunopharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
Interventions
- BIOLOGICAL LYL845
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2025-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05573035
The ClinicalTrials.gov registry entry for NCT05573035 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lyell Immunopharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LYL845 is the first listed.
NCT05573035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05573035 about?
NCT05573035 is a clinical study titled "A Study to Investigate LYL845 in Adults With Solid Tumors". This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally ad...
What is the current status of trial NCT05573035?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2022-12-19. Estimated completion is 2025-01-09.
What interventions are being tested in trial NCT05573035?
The interventions under investigation include: LYL845 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05573035?
This trial is sponsored by Lyell Immunopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.